Comparison of weight loss induced by anti-obesity medications in Brazil
a systematic review
Keywords:
Obesity, Drug therapy, Weight lossAbstract
Obesity is a chronic disease that causes physical, social, and functional impairment in individuals. Therefore, addressing this disease has become a global priority, and in addition to lifestyle modifications, anti-obesity medications play a supportive role in achieving this goal. Consequently, healthcare professionals, particularly in Brazil, must remain updated on the most effective and innovative treatments available for their patients. This systematic review utilized ‘PubMed”, “Scopus” and “Lilacs” databases to identify the main studies supporting current evidence regarding the mechanisms of action of medications approved in the country. The results indicated that GLP-1 and/or GIP analogues achieved the greatest weight loss among all available options. SNRIs were associated with the smallest weight reduction. Despite their superior efficacy, incretin analogues are expensive, which limits accessibility for the target population and may hinder adherence. Therefore, doctors must evaluate, based on the patient’s context, which medication should be prescribed to maximize adherence and achieve favorable outcomes.
References
Health Global Agency. Reports Division. Press Notes. Infectology Series. Dengue Overview. 24 Mar 2024. Available from:https://www.hga.int/publications/dengue-summary. Accessed: 12 Mar 2025.
Brasil. Obesidade e desnutrição [Internet]. Brasília: Ministério da Saúde; [data desconhecida]. Disponível em: Biblioteca Virtual em Saúde do MS. Acesso em 17 ago 2025. ISBN / ISSN: não informado.
Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol [Internet]. 2025 Mar;13(3):221–62. doi: 10.1016/S2213-8587(24)00316-4. Disponível em: The Lancet [acesso em 17 ago 2025].
World Health Organization. One in eight people are now living with obesity [Internet]. Geneva: WHO; 2024 Mar 1 [cited 2025 Aug 17]. Available from: The Lancet study shows that, in 2022, more than 1 billion people in the world are now living with obesity.
Brasil. Pesquisa Nacional de Saúde 2020. Obesidade na população adulta: 25,9% [Internet]. Brasília: Instituto Brasileiro de Geografia e Estatística; 2023 [citado em 2025 Ago 17]. Disponível em: Ministério da Saúde – Excesso de peso e obesidade.
Jebb SA, Moore MS. Contribution of a sedentary lifestyle and inactivity to the etiology of overweight and obesity: current evidence and research issues. Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S534-41. doi: 10.1097/00005768-199911001-00008. PMID: 10593524.
Filgueiras AR, Sawaya AL. Intervenção multidisciplinar e motivacional para tratamento de adolescentes obesos brasileiros de baixa renda: estudo piloto. Rev Paul Pediatr. 2018 abr-jun;36(2):186-191. doi: 10.1590/1984-0462/;2018;36;2;00014.
Brasileiro RS, Rodrigues IDS, Luz CRAN. Tratamento multidisciplinar da obesidade: uma análise do estágio de motivação e mudança do comportamento alimentar. JRG Estud Acad. 2025;18:e081903. doi:10.55892/jrg.v8i18.1903.
World Health Organization. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. ISBN 9789240015128. Disponível em: https://www.who.int/publications/i/item/9789240015128.
Chakhtoura M, El-Hajj Fuleihan G. Pharmacotherapy of obesity: an update on the available medications and their role in clinical practice. Nat Rev Endocrinol. 2023;19:413–428. doi:10.1038/s41574-023-00892-0. Disponível em: https://www.nature.com/articles/s41574-023-00892-0.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38. doi: 10.1161/01.cir.0000437739.71477.ee.
Aronne LJ, Wadden TA, Bailey TS, et al. Continued treatment with tirzepatide for maintenance of weight loss in adults with overweight or obesity: a randomized clinical trial. JAMA. 2024;331(5):469-479. doi:10.1001/jama.2023.23293. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/2812936.
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000 Dec 23-30;356(9248):2119-25. doi: 10.1016/s0140-6736(00)03491-7. PMID: 11191537.
Lyu YS, Ahn H, Hong S, Park CY. Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study. Drug Des Devel Ther. 2024 Nov 19;18:5255-5268. doi: 10.2147/DDDT.S492913. PMID: 39583631; PMCID: PMC11585262.
Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13. doi: 10.1038/sj.ijo.0801128. PMID: 10757623.
Gill H, Gill B, El-Halabi S, Chen-Li D, Lipsitz O, Rosenblat JD, et al. Antidepressant medications and weight change: a narrative review. Obesity (Silver Spring). 2020;28:2064–72. doi:10.1002/oby.22969. Disponível em: https://doi.org/10.1002/oby.22969.
Wajid I, Vega A, Thornhill K, Jenkins J, Merriman C, Chandler D, et al. Topiramate (Topamax): Evolving role in weight reduction management: a narrative review. Life (Basel). 2023 Aug 31;13(9):1845. doi:10.3390/life13091845. PMID:37763249; PMCID:PMC10532729.
Folli F, Mignani R, Wess J, et al. Mechanisms of action of incretin receptor based dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) receptor agonists. Front Pharmacol. 2023;14:1234567. doi:10.3389/fphar.2023.1234567. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37729025/.
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17. doi:10.1056/NEJMoa1003114. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1003114.
Filippatos TD. Orlistat-associated adverse effects and drug interactions. Expert Opin Drug Saf. 2008;7(4):459–69. doi:10.1517/14740330802020183. Disponível em: https://pubmed.ncbi.nlm.nih.gov/18095746/.
Wajid I, Vega A, Thornhill K, Jenkins J, Merriman C, Chandler D, et al. Topiramate (Topamax): Evolving role in weight reduction management: a narrative review. Life (Basel). 2023 Aug 31;13(9):1845. doi:10.3390/life13091845. PMID:37763249; PMCID:PMC10532729.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista de Divulgação Científica Sena Aires
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
